Whole-body pet/ct: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients

Nuclear Medicine Communications

Volumn 26, Issue 8, 2005, Pages 671-687

  Gorospe, Luis ^a   Raman, Subha ^b   Echeveste, Jon ^b   Avril, Norbert ^b   Herrero, Yolanda ^b   Hernández, Susana ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

FDG; Image fusion; Oncology; PET; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN;

ARTHROPATHY; BENIGN TUMOR; BONE MARROW; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FRACTURE; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART MUSCLE; HUMAN; INFECTION; INFLAMMATION; INSULIN BLOOD LEVEL; LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SKELETAL MUSCLE; THYROID GLAND; UROGENITAL SYSTEM;

ARTIFACTS; DIAGNOSTIC ERRORS; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; WHOLE-BODY COUNTING;

EID: 23044447727     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000171779.65284.eb     Document Type: Article

References (37)

1. Castellino RA, Hilton S, O'Brien JP, Portlock CS. Non-Hodgkin lymphoma: contribution of chest CT in the initial staging solution. Radiology 1996; 199:129-132.
2. Berlangeri SU, Scott AM. Metabolic staging of lung cancer. N Engl J Med 2000; 343:290-292.
3. Hopper KD, Singapuri K, Finkel A. Body CT and oncologic imaging. Radiology 2000; 215:27-40.
4. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191:371-377.
5. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23:1409-1415.
6. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET/CT system: initial results. Radiology 2002; 225:575-581.
7. Israel O, Mor M, Gaitini D, Keidar Z, Guralnik L, Engel A, et al. Combined functional and structural evaluation of cancer patients with a hybrid camera-based PET/CT system using 18F-FDG. J Nucl Med 2002; 43:1129-1136.
8. Charron M, Beyer T, Bohnen NN, Kinahan PE, Dachille M, Jerin J, et al. Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med 2000; 25:905-910.
9. Costa DC, Visvikis D, Crosdale I, Pigden I, Townsend C, Bomanji J, et al. Positron emission and computed X-ray tomography: a coming together. Nucl Med Commun 2003; 24:351-358.
10. Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. Am J Roentgenol 1997; 169:1675-1680.
11. Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 2002; 224:783-787.
12. Dizendorf EV, Treyer V, von Schulthess GK, Hany TF. Application of oral contrast media in coregistered positron emission tomography-CT. Am J Roentgenol 2002; 179:477-481.
13. Antoch G, Freudenberg LS, Stattaus J, Jentzen W, Mueller SP, Debatin JF, et al. Whole-body positron emission tomography-CT: optimized CT using oral and iv contrast materials. Am J Roentgenol 2002; 179:1555-1560.
14. Dizendorf EV, Hany TF, Buck A, von Schulthess GK, Burger C. Cause and magnitude of the error induced oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med 2003; 44:732-738.
15. Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol 2002; 37:169-174.
16. Engle H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996; 37:441-446.
17. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19:61-77.
18. 18 F-FDG PET/CT. J Nucl Med 2003; 44:170-176.
19. Barrington SF, Maisey MN. Skeletal muscle uptake of fluorine-18-FDG: effect of oral diazepam. J Nucl Med 1996; 37:1127-1133.
20. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Pre-clinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998; 16:173-180.
21. Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics 1998; 18:805-823.
22. Meyer M, Gast T, Raja S, Hubner K. Increased F-18 FDG accumulation in an acute fracture. Clin Nucl Med 1994; 19:13-14.
23. Shon IH, Fogelman I. F-18 FDG positron emission tomography and benign fractures. Clin Nucl Med 2003; 28:171-175.
24. Nakamoto Y, Osman M, Wahl RL. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18. Clin Nucl Med 2003; 28:302-307.
25. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23:1409-1415.
26. Bakheet SM, Saleem M, Powe J, Al-Amro A, Larsson SG, Mahassin Z. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin Nucl Med 2000; 25:273-278.
27. Kapucu LO, Meltzer CC, Townsend DW, Keenan RJ, Luketich JD. Fluorine-18-fluorodeoxyglucose uptake in pneumonia. J Nucl Med 1998; 39:1267-1269.
28. Alavi A, Gupta N, Alberini JL, Hickeson M, Adam LE, Bhargava P, et al. Positron emission tomography in nonmalignant thoracic disorders. Semin Nucl Med 2002; 32:293-321.
29. Boiselle PM, Pazz EF Jr, Vining DJ, Weissleder R, Shepard JA, McLoud TC. Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. Radiographics 1998; 18:1061-1069.
30. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms. Correlation of FDG uptake with histopathologic features. Am J Roentgenol 2000; 174:1005-1008.
31. Alibazoglu H, Megremis D, Ali A, LaMonica G. Injection artifact on FDG PET imaging. Clin Nucl Med 1998; 23:264-265.
32. Osman MM, Cohade C, Nakamoto Y, Marshall LT, Leal JP, Wahl RL. Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med 2003; 44:240-243.
33. Goerres GW, Burger C, Schwitter MR, Heidelberg TH, Seifert B, von Schulthess GK. PET/CT of the abdomen: optimizing the patient breathing pattern. Eur Radiol 2003; 13:734-739.
34. Antoch G, Freudenberg LS, Egelhof T, Stattaus J, Jentzen W, Debatin JF, et al. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med 2002; 43:1339-1342.
35. Nakamoto Y, Chin BB, Kraitchman DL, Lawler LP, Marshall LT, Wahl RL. Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. Radiology 2003; 227:817-824.
36. Kamel EM, Burger C, Buck A, von Schulthess GK, Goerres GW. Impact of metallic dental implants on CT-based attenuation correction in a combined PET/CT scanner. Eur Radiol 2003; 13:724-728.
37. Goerres GW, Ziegler SI, Burger C, Berthold T, von Schulthess GK, Buck A. Artifacts at PET and PET/CT caused by metallic hip prosthetic material. Radiology 2003; 226:577-584.